RAPID TREATMENT OF DEPRESSION AND SUICIDALITY
Greater reduction of depressive symptoms at 24 hours* (compared to those who received a placebo and oral antidepressant).†
DEMONTRATED EFFICACY IN MULTIPLE CLINICAL TRIALS
Those who took esketamine and an antidepressant experienced greater reductions of depressive symptoms at four weeks compared to those who received a placebo plus an oral antidepressant.†
IT MAY WORK WHEN OTHER TREATMENTS DO NOT
Most insurances will provide reimbursement for esketamine as an second-line treatment
O U R A P P R O A C H
At The Anxiety Center we offer intranasal esketamine an adjunct treatment options for patient with treatment resistant depression or acute suicidal thoughts or actions. SPRAVATO® (esketamine) is a an FDA approved alternative to intravenous ketamine that must be delivered at a certified SPRAVATO® treatment center. Current research indicates that it provides an important secondary approach to a significant number patients who may have exhausted more traditional means of managing treatment resistant depression and suicidal ideation. Although it is likely that there are multiple mechanisms at play scientists believe that esketamine works by modulating the activity of the N-methyl-D-aspartate (NMDA) receptor and is believed to work differently than currently available oral antidepressants. Although esketamine is not a treatment for everyone, it has been a life changing option for many. By coming to The Anxiety Center, you can be sure that you or your loved one will receive compassionate and effective care from experts committed to helping you achieve the best possible outcome.